Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growth
Open Access
- 26 April 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (29) , 47632-47641
Abstract
Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growth Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growthKeywords
This publication has 40 references indexed in Scilit:
- Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasisOncogene, 2016
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor MicroenvironmentTrends in Immunology, 2016
- Macrophages, Inflammation, and Lung CancerAmerican Journal of Respiratory and Critical Care Medicine, 2016
- Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant gliomaCancer Gene Therapy, 2014
- Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humansBlood, 2013
- Myeloid-derived Suppressor Cells (MDSCs) in Gliomas and Glioma-DevelopmentImmunological Investigations, 2012
- The cellular origin for malignant glioma and prospects for clinical advancementsExpert Review of Molecular Diagnostics, 2012
- Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastomaNeuro-Oncology, 2011
- Immune responses to malignanciesJournal of Allergy and Clinical Immunology, 2010
- CD80 in Immune Suppression by Mouse Ovarian Carcinoma–Associated Gr-1+CD11b+ Myeloid CellsCancer Research, 2006